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Insulin actionThe exact mechanism by which ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibits insu-
lin signaling is not known. ENPP1 contains two somatomedin-B-like domains (i.e. SMB 1 and 2) involved in
ENPP1 dimerization in animal cells. The aim of the present study was to investigate if these domains modu-
late ENPP1 inhibitory activity on insulin signaling in human insulin target cells (HepG2). ENPP1 (ENPP1–3′
myc), ENPP1 deleted of SMB 1 (ENPP1-ΔI-3′myc) or of SMB 2 (ENPP1-ΔII-3′myc) domain were cloned in
frame with myc tag in mammalian expression vector pRK5. Plasmids were transiently transfected in
human liver HepG2 cells. ENPP1 inhibitory activity on insulin signaling, dimerization and protein–protein in-
teraction with insulin receptor (IR), reported to mediate the modulation of ENPP1 inhibitory activity, were
studied. As compared to untransfected cells, a progressive increase of ENPP1 inhibitory activity on insulin-
induced IR β-subunit autophosphorylation and on Akt-S473 phosphorylation was observed in ENPP1–3′
myc, ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc cells. Under non reducing conditions a 260 kDa homodimer,
indicating ENPP1 dimerization, was observed. The ratio of non reduced (260 kDa) to reduced (130 kDa)
ENPP1 was signiﬁcantly decreased by two thirds in ENPP1-ΔII-3′myc vs. ENPP1–3′myc but not in ENPP1-
ΔI-3′myc. A similar ENPP1/IR interaction was detectable by co-immunoprecipitation in ENPP1–3′myc,
ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc cells. In conclusion, SMB 1 and SMB 2 are negative modulators of
ENPP1 inhibitory activity on insulin signaling. For SMB 2 such effect might be mediated by a positive role
on protein dimerization.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Insulin resistance is a major contributor to type 2 diabetes and
cardiovascular disease and thus to morbidity and mortality in devel-
oped countries [1].
Themolecularmechanisms of insulin resistance aremostly unknown
[2]. A candidate molecule is the class II transmembrane glycoprotein
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l rights reserved.binds to the insulin receptor (IR) β-subunit and inhibits IR β-subunit
autophosphorylation and downstream signaling [3–6]. As a matter of
fact, in both cultured cells [3,7–11] and rodents [12,13], ENPP1 over-
expression affects insulin signaling and action. In addition, increased
ENPP1 expression has been observed in several tissues of insulin-
resistant subjects [5,14–17]. Further support to the notion that ENPP1
may play a role on human insulin resistance derives from the ENPP1
K121Q polymorphism (rs1805101) [18], with Q121 being a gain of func-
tion aminoacid substitution with a stronger inhibitory activity on IR sig-
naling [9,19] and a genetic determinant of insulin resistance-related
abnormalities in several [20–22], although not all [23], studies.
The exact mechanism by which ENPP1 inhibits IR β-subunit auto-
phosphorylation and downstream signaling is not yet understood.
ENPP1 is a homodimer of about 130 kDa [24,25]. The monomers
consist of a short intracellular N-terminal domain (10–80 residues)
involved in the targeting to plasmamembrane [26], a single transmem-
brane domain (~20 residues) and a large extracellular part (~800 resi-
dues) comprising several domains. Among these, are two consecutive
somatomedin-B-like (i.e. SMB 1 and 2) domains which have been
reported to take part of mouse ENPP1 dimerization in monkey cells
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on insulin signaling is not known. The aim of the present study was to
address this issue in human insulin target cells.
2. Materials and methods
2.1. Cell lines
HepG2 cells (ATCC, Manassas, USA) were maintained at 37 °C and
5% CO2 in DMEM/F12 containing 10% FBS.
2.2. Plasmids
Full-length cDNA of human ENPP1 was kindly provided by Dr. I.D.
Goldﬁne (San Francisco, University of California, USA). ENPP1 open
reading framewas cloned in framewithmyc tag inmammalian expres-
sion vector pRK5 (ENPP1–3′myc, expected molecular weight (MW)
119.6 kDa); ENPP1 lacking amino acids from 107 to 144 which repre-
sent SMB 1 domain (ENPP1-ΔI-3′myc, expected MW 115.5 kDa) and
ENPP1 lacking amino acids from 145 to 186, which represent the SMB
2 domain (ENPP1-ΔII-3′myc, expectedMW110.9 kDa)were generated
by mutagenesis of pRK5 ENPP1–3′myc by using ExSite PCR-Based
Site-Directed Mutagenesis Kit according to the manufacturer's instruc-
tions (Stratagene), by using the following primers:
• ENPP1-ΔI-3′myc:
5′-TATATGGACTTGCAACAAATTCAGGTGTGGTGAG-3′
5′-AACTTCTTTGGCACAGCTTGGTTTCAACCC-3′;
• ENPP1-ΔII-3′myc:
5′-AGTTGGGTAGAAGAACCATGTGAGAGCATTAATG-3′
5′-ATGTTCTGGTTCTATGCACGTCTCCTGGTAATCTAAAC-3′.
2.3. Transfections
HepG2 cells were transiently transfected with ENPP1–3′myc,
ENPP1-ΔI-3′myc, ENPP1-ΔII-3′myc and mock cDNAs as appropriate
by using TransIT reagent according to the manufacturer's instructions
(Mirus, Italy), and then starved overnight in DMEM/F12 containing
0.5% FBS before experiments. ENPP1 protein expression in each condi-
tion was evaluated by western blot analysis. Transfection efﬁciency
was evaluated by immunoﬂuorescence after co-transfecting pcDNA3–
EGFP with either ENPP1–3′myc or ENPP1-ΔI-3′myc or ENPP1-ΔII-3′
myc, respectively. Fluorescent cells were always >55% across all
experimental conditions.
2.4. Western blot
Cells lysates were separated by SDS-PAGE and transferred to ni-
trocellulose membrane (Amersham Pharmacia Biotech). Blots were
probed with speciﬁc antibodies and the chemiluminescent substrate
(Super Signaling West Pico Thermo Scientiﬁc, Pierce or ECL by
Amersham, GE Healthcare) was used for detection following HRP-
conjugated antibodies (Santa Cruz Biotechnology, CA) incubation.
Gel images were acquired by using Molecular Imager ChemiDoc XRS
(Biorad) and analyzed by using Kodak Molecular Imaging Software
4.0 or IMAGEJ 1.40 g (Wayne Rasband, NIH).
2.5. IR β-subunit autophosphorylation
Following human insulin stimulation (10−6 M for 5 min at 37 °C)
and cell lysis, equal amount of proteins was immunoprecipitated with
anti-PY antibody (4G10 Platinum, Millipore, Italy) and analyzed by
western blot with anti IR β-subunit antibody (C19, Santa Cruz
Biotechnology, CA). IR β-subunit autophosphorylation was calculated
as percentage of that in stimulated untransfected cells (i.e. IR band in-
tensities of insulin-stimulated transfected cells/IR band intensities ofinsulin-stimulated untransfected cells×100) and expressed as
mean±SEM. When data were analyzed after adjusting for ENPP1
protein expression levels, the above described values were further di-
vided by ENPP1 band intensities. Both the upper and the lower bands
were considered for quantiﬁcation of ENPP1–3′myc and ENPP1-ΔI-3′
myc expression.
2.6. Insulin downstream signaling
Following insulin stimulation (10−6 M for 5 min at 37 °C) and cell
lysis, equal amount of protein was analyzed by western blot with the
speciﬁc anti-phospho-Akt-S473 antibody (Cell Signaling, MA). The
blot was then stripped and re-probed with anti-Akt antibody for nor-
malization (Cell Signaling, MA). Data were calculated as percentage of
that in stimulated untransfected cells (i.e. Akt-Ser473 band intensities
of insulin-stimulated transfected cells/Akt-Ser473 band intensities of
insulin-stimulated untransfected cells×100). When data were ana-
lyzed after adjusting for ENPP1 protein expression levels the above
described values were further divided by ENPP1 band intensities.
Both the upper and the lower bands were considered for quantiﬁca-
tion of ENPP1–3′myc and ENPP1-ΔI-3′myc expression.
2.7. ENPP1 dimerization
Equal amount of proteins lysate was either supplemented with
SDS-electrophoresis buffer in the absence of reducing agent (i.e.
non-reduced proteins) or supplementedwith SDS-electrophoresis buff-
er in the presence of reducing agent (i.e. reduced proteins) boiled and
analyzed by western blot with anti c-myc antibody (9E10, Roche,
Italy). Data were calculated as native to denatured sample ratio and
expressed as mean±SEM.
2.8. ENPP1/IR interaction
ENPP1/IR interaction was performed as previously described [19].
Brieﬂy, following human insulin stimulation (10−6 M for 5 min at
37 °C) and cell lysis, proteins (i.e. 1 mg) were immunoprecipitated
with the 83–14 anti-IR α-subunit antibody (Invitrogen, Italy) and an-
alyzed by western blot analysis by using anti c-myc antibody (9E10,
Roche, Italy). IR interaction was corrected for IR and ENPP1 expres-
sion levels and expressed as mean±SEM.
2.9. Statistical analysis
Differences between mean values were evaluated by unpaired or
paired Student's t test, as appropriate.
3. Results
3.1. ENPP1 constructs
To elucidate the role of SMB domains of ENPP1 on IR activation,
we generated two deletion mutants (i.e. ENPP1-ΔI-3′myc, ENPP1-
ΔII-3′myc) whose salient features are described in Methods (Fig. 1).
According to previous report [28], two bands appeared for myc-
tagged ENPP1, whose apparent molecular mass is 135–145 kDa. This
was also the case for ENPP1-ΔI-3′myc (apparent molecular mass of
133–143 kDa) but not for ENPP1-ΔII-3′myc for which only a single
band was observed (apparent molecular mass of 134 kDa). Accordingly
to what reported for ENPP1 [28], the doublet observed for ENPP1-ΔI-3′
myc, might be the consequence of post-translational modiﬁcation;
therefore, distinct protein modiﬁcation processes between ENPP1-ΔI-3′
myc and ENPP1-ΔII-3′myc may account for their different aspect at
western blot analysis.
Fig. 1. ENPP1 constructs. Cells were either transfected or not with ENPP1–3′myc,
ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc cDNA respectively as described in Methods.
No bands were detectable in untransfected HepG2 cells (lane 1). Apparent molecular
mass of ENPP1–3′myc, which appears as two bands, was 135–145 kDa (lane 2).
Deletion of SMB 1 and SMB 2 domains caused a slight decrease of the apparent molec-
ular mass, which corresponded to 133–143 kDa for ENPP1-ΔI-3′myc (lane 3) and
134 kDa for ENPP1-ΔII-3′myc (lane 4). A representative blot out of 3 is shown.
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the three different ENPP1 constructs, thus suggesting differences also in
protein stability and degradation.Fig. 2. IR autophosphorylation. Cells were either transfected or not with ENPP1–3′myc, ENP
as described in Methods. Upper panel: bars represent quantitative analysis of IR β-subunit
(C). Inset: bars represent quantitative analysis of ENPP1 constructs inhibitory activity expr
that observed in untransfected cells. Data are corrected for ENPP1 expression levels, as de
stimulated cells. *pb0.03 vs. ENPP1–3′myc insulin stimulated cells. ^pb0.03 vs. ENPP1-ΔI-
was immunoprecipitated with anti-phosphotyrosine 4G10 antibody, separated by SDS-PA
evaluate ENPP1 protein content the same ﬁlter was probed with anti c-myc speciﬁc antibo3.2. IR β-subunit autophosphorylation
IR β-subunit autophosphorylation was studied in human liver
HepG2 cells. To this purpose, cells were transfected with either
ENPP1–3′myc, ENPP1-ΔI-3′myc or ENPP1-ΔII-3′myc cDNA and
then stimulated with insulin, as described in Methods. Immunoblot
analysis showed that insulin stimulation induced IR β-subunit
autophosphorylation in HepG2 control cells (Fig. 2, 2nd bar and
lane 2, upper blot). As compared to control cells, this effect was
progressively reduced in ENPP1–3′myc (21% reduction, 4th bar and
lane 4, upper blot), ENPP1-ΔI-3′myc (27% reduction, 6th bar and
lane 6, upper blot) and ENPP1-ΔII-3′myc (49% reduction, 8th bar
and line 8, upper blot). No differences in insulin-induced IR
β-subunit autophosphorylation were observed among ENPP1–3′
myc, ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc HepG2 transfected
cells (4th, 6th, and 8th bars and lanes 4, 6, and 8 respectively).
After adjustment for ENPP1 expression levels (which are largely
different as shown in Fig. 2, lower blot), ENPP1 inhibitory activity
on insulin-induced IR β-subunit autophosphorylation in ENPP1-
ΔI-3′myc and ENPP1-ΔII-3′myc was signiﬁcantly increased, as
compared to that of ENPP1–3′myc (inset Fig. 2, 2nd and 3rd bars
vs. 1st bar, pb0.03 for both). In addition, the inhibitory effect of
ENPP1-ΔII-3′myc was signiﬁcantly increased as compared to that
observed in ENPP1 ΔI-3′myc (inset Fig. 2, 3rd bar vs. 2nd bar).
Thus, taking into account the intrinsic different ENPP1 expressionP1-ΔI-3′myc and ENPP1-ΔII-3′myc cDNA respectively and then stimulated with insulin
autophosphorylation calculated as percentage of that of stimulated untransfected cells
essed as percent reduction of insulin-induced IR autophosphorylation, as compared to
scribed in Methods. Data are means±SEM, n=3 experiments. §p≤0.02 vs. C insulin
3′myc insulin stimulated cells. Lower panel: equal amount of protein from cell lysates
GE, and analyzed by western blot with anti-IR β-subunit antibody (upper blot); to
dy (lower blot). Representative immunoblots are shown.
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different ENPP1 constructs on IR autophosphorylation.
Tomake sure that the differences we observed across different ENPP1
constructs were not entirely imputable to their different protein expres-
sion levels, we performed additional experiments by transfecting increas-
ing amounts of ENPP1–3′myc (0.5 μg), ENPP1-ΔI-3′myc (2 μg) and
ENPP1-ΔII-3′myc (3 μg) cDNA, in order to obtain similar expression
levels for all constructs (Supplementary Fig. 1A, lanes 3–8). Under
these experimental conditions, as compared to control cells, insulin
stimulation of IR β-subunit autophosphorylation was progressively
lower in ENPP1–3′myc (Supplementary Fig. 1B, 18% reduction, 4th bar
and lane 4), ENPP1-ΔI-3′myc (Supplementary Fig. 1B, 30% reduction,
6th bar and lane 6) and ENPP1-ΔII-3′myc (Supplementary Fig. 1B, 36%
reduction, 8th bar and line 8). In addition, as compared to that of
ENPP1–3′myc, ENPP1 inhibitory activity was signiﬁcantly increased in
ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc (Supplementary Fig. 1B, 2nd and
3rd bars vs. 1st bar). Finally, ENPP1-ΔII-3′myc inhibitory activity tended
to be increased as compared to that of ENPP1 ΔI-3′myc (Supplementary
Fig. 1, 3rd bar vs. 2nd). Thus, also in a different experimental approach,
in which a similar ENPP1 expression level was artiﬁcially obtained,
we were able to conﬁrm that both ENPP1-ΔI-3′myc and ENPP1-ΔII-3′
myc are stronger inhibitors of IR autophosphorylation, as compared to
ENPP1–3′myc.
3.3. Insulin downstream signaling
To characterize the effect of ENPP1 SMB domains on downstream
insulin signaling in typical insulin target cells, we investigatedFig. 3. Insulin downstream signaling. Cells were either transfected or not with ENPP1–3′my
insulin as described in Methods. Upper panel: bars represent quantitative analysis of Akt-S47
Inset: bars represent quantitative analysis of ENPP1 constructs inhibitory activity expressed
observed in untransfected cells. Data are corrected for ENPP1 expression levels, as describ
ENPP1–3′myc. Lower panel: equal amount of protein from cell lysates was separated by S
(upper blot). To evaluate Akt protein content, the same ﬁlter was stripped and reprobed w
ENPP1 protein content equal amount of denatured protein lysate was separated by SDS-PAGE
same experiment is shown in Fig. 2.Akt-S473 insulin-induced phosphorylation in HepG2 cells. Immuno-
blot analysis showed that insulin stimulation induced Akt-S473 phos-
phorylation in HepG2 control cells (Fig. 3, 2nd bar and lanes 2, upper
blot). As compared to control cells, this effect was signiﬁcantly
reduced in ENPP1–3′myc (40% reduction, 4th bar and lane 4, upper
blot) ENPP1-ΔI-3′myc (50% reduction, 6th bar and lane 6, upper
blot) and ENPP1-ΔII-3′myc (52% reduction, 8th bar and lane 8,
upper blot). No differences in insulin-induced Akt-S473 phosphoryla-
tion were observed among ENPP1–3′myc, ENPP1-ΔI-3′myc and
ENPP1-ΔII-3′myc HepG2 transfected cells (4th, 6th, and 8th bars
and lanes 4, 6, and 8 respectively). Similarly to what observed on IR
autophosphorylation, when data were adjusted for ENPP1 expres-
sion, as compared to ENPP1–3′myc, ENPP1 inhibitory activity on
insulin-induced Akt-S473 phosphorylationwas progressively and sig-
niﬁcantly increased in ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc HepG2
transfected cells (inset Fig. 3, 2nd and 3rd bars vs. 1st bar, pb0.03 for
both). So, also in this case, as in that of IR autophosphorylation, taking
into account the intrinsic different ENPP1 expression level allows
unraveling differences in the deleterious effect of the different ENPP1
constructs on Akt-S473 phosphorylation.
Similarly to what described for IR autophosphorylation, additional
experiments were carried out in cells expressing similar amounts of
the three ENPP1 constructs, as obtained by transfecting increasing
amounts of ENPP1 cDNAs (see above). Under these experimental con-
ditions, as compared to control cells, insulin stimulation of Akt-S473
phosphorylation was progressively lower in ENPP1–3′myc (Supple-
mentary Fig. 1C, 21% reduction, 4th bar and lane 4, upper blot),
ENPP1-ΔI-3′myc (Supplementary Fig. 1C, 45% reduction, 6th bar andc, ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc cDNA respectively and then stimulated with
3 phosphorylation calculated as percentage of that of stimulated untransfected cells (C).
as percent reduction of insulin-induced Akt-S473 phosphorylation, as compared to that
ed in Methods. Data are means±SEM, n=5 experiments. §p≤0.02 vs. C. *pb0.03 vs.
DS-PAGE and analyzed by western blot with anti-Akt-S473 phosphorylation antibody
ith speciﬁc antibody (lower blot). Representative immunoblots are shown. To evaluate
and probed with anti c-myc speciﬁc antibody The ENPP1 protein content blot from the
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reduction, 8th bar and lane 8, upper blot). In addition, as compared to that
of ENPP1–3′myc, ENPP1 inhibitory activity was signiﬁcantly increased in
ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc (Supplementary Fig. 1C, 2nd and
3rd bars vs. 1st bar). Thus, as for IR autophosphorylation studies, the
two different approaches we used have provided similar data indicating
an increased inhibitory activity of ENPP1-ΔI-3′myc and ENPP1-ΔII-3′
myc on Akt phosphorylation.
All these data strongly indicate that the inhibition exerted by
ENPP1 on IR β-subunit autophosphorylation and downstream signal-
ing is dependent upon SMB1 and SMB2 regions which act as inhibito-
ry domains of such effects.
3.4. ENPP1 dimerization
To ascertain the role of SMBdomains on ENPP1 dimerization, HepG2
cells were transiently transfected with either ENPP1–3′myc, ENPP1-
ΔI-3′myc or ENPP1-ΔII-3′myc cDNA and then equal amount of either
not reduced or reduced protein lysate, was loaded on SDS PAGE and
analyzed by western blot.
In HepG2 transfected with ENPP1–3′myc, a clearly visible
homodimer was observed at about 260 kDa under non reducing con-
ditions (Fig. 4, left blot, line 2) thus indicating that ENPP1 dimeriza-
tion takes place in human liver cells. A similar ﬁnding was observed
in ENPP1-ΔI-3′myc, but not in ENPP1-ΔII-3′myc, where a muchFig. 4. ENPP1 dimerization. Cells were either transfected or not with ENPP1–3′myc,
ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc cDNA respectively as described in Methods.
Upper panel: equal amount of non reduced (left blot) and reduced (right blot)
protein lysate was separated by SDS-PAGE and probed with anti c-myc speciﬁc antibody.
Representative immunoblots are shown. Lower panel: non reduced to reduced sample
ratio represents quantitative analysis of ENPP1 dimerization (mean±SEM, n=4 experi-
ments). *pb0.03 vs. ENPP1–3′myc;. ^pb0.03 vs. ENPP1-ΔI-3′myc.fainter band was visible (Fig. 4, left blot lines 3 and 4 respectively).
When the ratio of non reduced (260 kDa, left blot) to reduced
(130 kDa, right blot) sample was assessed, a signiﬁcant reduction was
observed for ENPP1-ΔII-3′myc as compared to both ENPP1–3′myc and
ENPP1-ΔI-3′myc which, in contrast, showed similar results (Fig. 4,
lower panel). It should be noted that, although ENPP1-ΔII-3′myc
forms less dimers, no monomers were detectable under non reducing
conditions (Fig. 4 left blot lane 4), a likely consequence of protein
stability and/or degradation. As expected in untransfected control
cells, no bands were observed under both non reduced and reduced
conditions (Fig. 4 lane 1, left blot and lane 1 right blot).
These data suggest that in human cells SMB 2, but not SMB 1,
domain takes part in ENPP1 dimerization.3.5. ENPP1/IR interaction
Previous studies have suggested that the ENPP1 inhibitory activity
on IR β-subunit autophosphorylation is mediated by ENPP1/IR inter-
action [3,9,19]. In HepG2 cells, after insulin stimulation, an interaction
was clearly detectable by co-immunoprecipitation between IR and
ENPP1–3′myc, ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc (Fig. 5 lanes
2–4). As expected, no band on IR/ENPP1 interaction was observed in
untransfected control cells (Fig. 5 lane 1).Fig. 5. ENPP1/IR interaction. Cells were either transfected or not with ENPP1–3′myc,
ENPP1-ΔI-3′myc and ENPP1-ΔII-3′myc cDNA respectively and stimulated with
insulin as described in Methods. Upper panel: to evaluate ENPP1 protein content,
equal amount of denatured protein lysate was separated by SDS-PAGE and probed
with anti c-myc speciﬁc antibody (upper blot). Equal amount of protein from cell
lysates was immunoprecipitated by using anti-IRα-subunit 83–14 antibody, separat-
ed by SDS-PAGE and probed with anti c-myc (middle panel) and anti IR β-subunit
(lower panel) speciﬁc antibodies. Lower panel: bars represent quantitative analysis
of ENPP1/IR interaction corrected for IR and ENPP1 expression levels in each experi-
ment (mean±SEM, n=6 experiments).
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not affect interaction between ENPP1 and IR.
3.6. Mock transfected control experiments
Baseline and insulin-stimulated IR β-subunit autophosphorylation
and Akt-S473 phosphorylation were totally superimposable in
untransfected and mock transfected HepG2 cells (n=3 for each
experiment; data not shown). As expected, neither in untransfected,
nor in mock transfected cells we were able to observe bands related
to ENPP1/IR interaction and ENPP1 dimerization (data not shown).
All these ﬁndings validate the use of untransfected HepG2 cells as a
proper control in all experiments.
4. Discussion
The results we here report help get some insights on which pro-
tein domains are involved in the negative modulation of insulin re-
ceptor activation and downstream signaling exerted by ENPP1.
Our ﬁndings clearly indicate that SMB 1 and, to some extent even
more profoundly, SMB 2 act as inhibitory domains of ENPP1 function.
As far as SMB 2 is concerned, such effect is accompanied by a positive
role on protein dimerization, thus suggesting a cause–effect relation-
ship between protein dimerization and ENPP1 inhibitory activity on
insulin signaling. Since this was not the case for SMB 1, it is likely
that the two domains partly act through different mechanisms on
the deleterious role of ENPP1 on insulin signaling with only that of
SMB 2 being mediated by protein dimerization.
Neither SMB 1 nor SMB 2 affects the interaction between ENPP1 and
IR which has been reported to mediate the modulation of ENPP1 inhibi-
tory activity on insulin receptor activation and downstream signaling [3].
A limitation of our study is represented by the indirect ap-
proach we used to evaluate IR autophosphorylation. Since we
ﬁrst immunoprecipitated with anti-phosphotyrosines 4G10 antibody
and then blotted with anti-IR antibody, it might be hypothesized that
some phosphotyrosines, which are not accessible to the antibody,
have not been detected by our approach, thus biasing our results.
However, if this happens, it should occur across all experimental condi-
tions, thusmaking very unlikely it had altered the relative differences in
IR autophosphorylation we observed.
Although not our primary aim, this study also reports for the ﬁrst
time that ENPP1 dimerization does occur in human insulin target cells
and that SMB 2, but not SMB 1, domain is instrumental for it. Data
here presented are somehow at variance with those of Gijsbers et
al. [27] supporting that both SMB 1 and SMB 2 are involved in
mouse ENPP1 dimerization in monkey cells. Differences in the cellular
model as well as in the method used for studying protein dimeriza-
tion might explain the different results. Also species-speciﬁcity may
have played a role, making SMB 1 domain important for mouse but
not for human ENPP1 dimerization.
5. Conclusions
In conclusion, SMB 1 and SMB 2 are important modulators of ENPP1
inhibitory activity on insulin receptor activation and downstream sig-
naling. Further investigations, including those on stably transfected
cells, are needed to deeper address the intimate molecular action of
ENPP1 whichwill hopefully pave the way for new treatments of insulin
resistance and related sequels.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.10.017.
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